Dr. Hutson on Safety Considerations With Cabozantinib in mRCC

Thomas Hutson, DO, PharmD, discusses key safety considerations with cabozantinib in patients with metastatic renal cell carcinoma.

Thomas Hutson, DO, PharmD, director, Urologic Oncology Program, co-chair, Urologic Cancer Research and Treatment Center, Baylor University Medical Center, professor of medicine, Texas A&M College of Medicine, discusses key safety considerations with cabozantinib (Cabometyx) in patients with metastatic renal cell carcinoma (mRCC).

Cabozantinib is a potential treatment option for patients with mRCC, says Hutson. Initially, patients receiving cabozantinib should be monitored every 2 to 3 weeks for blood pressure changes, mouth sores, diarrhea, and hypertension, Hutson explains. Once dosing and adverse effect (AE) management strategies are in place, patients can be monitored every 6 to 8 weeks, Hutson says.

Additionally, it is important to establish a relationship with the patient in which they feel comfortable relaying any AEs that arise and understand that dose reduction is an option, concludes Hutson.